Lineage Cell Therapeutics Q2 net income $1.5 million as revenue falls to $1.1 million
Lineage Cell Therapeutics reported second quarter 2026 results, with net income attributable to Lineage of $1.5 million, or $0.01 per basic share, compared with a net loss of $30.5 million a year earlier. The profit was driven mainly by a $9.4 million non-cash gain from remeasuring warrant liabilities, while revenue fell to $1.1 million and the operating loss was $8.9 million, and diluted loss per share was $(0.03).
Key points
- Total revenues were $1.1 million, down from $2.8 million a year earlier, mainly due to lower Roche collaboration revenue.
- Loss from operations narrowed to $8.9 million from $19.8 million, which included a $14.8 million impairment in the prior-year quarter.
- Other income of $10.5 million, mainly a $9.4 million warrant liability gain, produced net income attributable to Lineage of $1.5 million.
- Cash, cash equivalents and marketable securities were $50.8 million as of June 30, 2026, which the company expects to support planned operations into Q3 2028.
The filing
Written by AI on Nov 9, 2026, 8:29 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 06, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.